The financials
Intellia Therapeutics, Inc. by the numbers
Intellia Therapeutics, Inc. (NTLA) reported revenue of $15M in Q1 2026 (quarter ended March 31, 2026), down 9.5% from the same quarter a year earlier. That came with net loss of $96M. For the full year FY2025, revenue was $68M (+17% year on year) and net income −$413M. Its largest product in 2023-Q1 was Research And Development Services at $41M, 100% of the disclosed total, just ahead of Research Materials Shippmet Services at 0.2%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $15M | $17M | −9.5% |
| Operating income | −$101M | −$121M | n/a |
| Net income | −$96M | −$114M | n/a |
| Diluted EPS | −$0.81 | −$1.10 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Research And Development Services | $41M | 100% |
| Research Materials Shippmet Services | $100K | 0.2% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2025Total $1.0M (+400%)
Segment Latestquarter on quarteryear on year
- Research Materials Shippmet Services$1.0M$1.0MQoQ +400%year on year -+400%-